Microstent reduces medication use


Intracanalicular device providing durable IOP reduction as standalone procedure

The open study enrolled 69 patients at 7 centres. Forty eyes underwent microinvasive glaucoma surgery (MIGS) alone and 29 had combination phacoemulsification. After one year of follow-up in both subgroups, both mean IOP and mean medication use were significantly reduced from baseline. No serious complications occurred and there were no cases of device migration or perforation.

"MIGS is an evolving therapeutic option conceived to treat glaucoma surgically more safely than trabeculectomy while still maintaining traditional options," claimed Dr Samuelson, founding partner, Minnesota Eye Consultants, Minneapolis, Minnesota, USA, and medical monitor for the multinational study. "However, the MIGS procedures are often performed in conjunction with cataract extraction, which makes it difficult to know what is the pressure effect from the MIGS procedure itself.

"Not only does the stent occupy nearly 8 mm of Schlemm's canal, providing access for aqueous to multiple collector channels, but it also dilates the canal," Dr Samuelson said. "Laboratory studies have shown that this true stenting further improves aqueous outflow."

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Related Content
© 2023 MJH Life Sciences

All rights reserved.